MedTrace Logo

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

NCT01249001 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-04-19

No results posted yet for this study

Summary

The primary objective of this study is to compare the absorption of a prepared aprepitant oral suspension with that of the aprepitant capsule in children being treated with chemotherapy agents that are likely to cause vomiting.

Conditions

Interventions

DRUG

Oral Aprepitant

Subject will receive an oral suspension containing 125mg of Aprepitant

DRUG

Aprepitant

Subjects will receive a 125 mg Aprepitant capsule

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Lee Dupuis, RPh, MScPhm, ACPR, FCSH · The Hospital for Sick Children, Toronto Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2016-09-28
Completion
2016-09-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01249001 on ClinicalTrials.gov